Postpartum haemorrhage (PPH) remains a leading cause of maternal morbidity and mortality worldwide, causing up to 75% of severe maternal morbidity.
Massive obstetric haemorrhage remains a major cause of maternal death attributable to hypofibrinogenaemia. Transfusion of large volumes of fresh frozen plasma (FFP) is required to normalise fibrinogen levels.
Postpartum hemorrhage (PPH) is related to several factors but is frequently associated with coagulopathy with maternal mortality. Fibrinogen is a very important agent for bleeding. When its concentration...
Maintaining the plasma fibrinogen concentration is important to limit excessive perioperative blood loss. This article considers the evidence for this statement, and questions the justification for using cryoprecipitate rather than...
Here we compare fibrinogen concentrate with fresh frozen plasma and cryoprecipitate for treating fibrinogen deficiencies in different clinical contexts.
In cases of critical obstetric hemorrhage leading to extreme hypofibrinogenemia, fibrinogen is the marker that indicates the critical severity, and early fibrinogen supplementation centering on hemostatic resuscitation is...
We conducted an in vitro study to explore whether substitution with fibrin-stabilizing factor XIII (FXIII) combined with fibrinogen promotes further improvement of clot formation, and whether fibrinogen administration as concentrate or fresh frozen plasma (FFP) results in comparable effects.
Find out about "First-Line Fibrinogen Concentrate for Bleeding Trauma" in this publication digest.
Postpartum haemorrhage (PPH) can be exacerbated by haemostatic failure. We hypothesized that early fibrinogen replacement, guided by viscoelastometric testing, reduces blood product usage and bleed size.
Fibrinogen deficiency is a clinical challenge for bleeding management. We discuss both congenital and acquired fibrinogen deficiencies.